Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14859165 | 0.84 | ALDH1A1 (0.51) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL14860314 | 0.83 | NPC1 (0.50) | TDP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL220071 | 0.82 | SMN1; SMN2 (0.37) | TDP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL220680 | 0.82 | MEN1 (0.41) | TDP1MEN1KMT2ARAB9AMAPT | |
| SCHEMBL5713553 | 0.81 | NPC1 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL222250 | 0.79 | MEN1 (0.36) | TDP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5713570 | 0.78 | NPSR1 (0.54) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5713503 | 0.78 | RAB9A (0.54) | TDP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2862569 | 0.76 | RAB9A (0.59) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL220188 | 0.76 | MEN1 (0.37) | TDP1MEN1KMT2ARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583752-B1 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-7087761-B2 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1583752-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004060879-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | CBR3, CBR1, OXTR | THRB 873/4885TDP1 4722/4885MEN1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.